Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Novo Nordisk A/S stock

Learn how to easily invest in Novo Nordisk A/S stock.

Novo Nordisk A/S is a biotechnology business based in the US. Novo Nordisk A/S shares (NVO) are listed on the NYSE and all prices are listed in US Dollars. Novo Nordisk A/S employs 50,816 staff and has a trailing 12-month revenue of around $157.3 billion.

How to buy shares in Novo Nordisk A/S

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NVO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Novo Nordisk A/S stock price (NYSE: NVO)

Use our graph to track the performance of NVO stocks over time.

Novo Nordisk A/S shares at a glance

Information last updated 2022-10-02.
Latest market close$99.63
52-week range$90.40 - $121.50
50-day moving average $105.89
200-day moving average $107.13
Wall St. target price$126.42
PE ratio 34.5937
Dividend yield $11.15 (1.61%)
Earnings per share (TTM) $2.88

Buy Novo Nordisk A/S shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Novo Nordisk A/S stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Novo Nordisk A/S price performance over time

Historical closes compared with the close of $99.63 from 2022-09-30

1 week (2022-09-27) 3.89%
1 month (2022-09-02) -2.55%
3 months (2022-07-01) -10.76%
6 months (2022-04-04) -12.46%
1 year (2021-10-04) 2.77%
2 years (2020-10-02) 45.11%
3 years (2019-10-04) 94.13%
5 years (2017-10-04) 102.17%

Is Novo Nordisk A/S stock undervalued or overvalued?

Valuing Novo Nordisk A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Novo Nordisk A/S's P/E ratio

Novo Nordisk A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Novo Nordisk A/S shares trade at around 35x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Novo Nordisk A/S's PEG ratio

Novo Nordisk A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7345. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Novo Nordisk A/S's EBITDA

Novo Nordisk A/S's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $72 billion.

The EBITDA is a measure of a Novo Nordisk A/S's overall financial performance and is widely used to measure a its profitability.

Novo Nordisk A/S financials

Revenue TTM $157.3 billion
Operating margin TTM 42.68%
Gross profit TTM $117.1 billion
Return on assets TTM 22.25%
Return on equity TTM 72.19%
Profit margin 32.14%
Book value $32.81
Market capitalisation $225.4 billion

TTM: trailing 12 months

Novo Nordisk A/S share dividends


Dividend payout ratio: 7.24% of net profits

Recently Novo Nordisk A/S has paid out, on average, around 7.24% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.61% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk A/S shareholders could enjoy a 1.61% return on their shares, in the form of dividend payments. In Novo Nordisk A/S's case, that would currently equate to about $11.15 per share.

While Novo Nordisk A/S's payout ratio might seem low, this can signify that Novo Nordisk A/S is investing more in its future growth.

Novo Nordisk A/S's most recent dividend payout was on 22 August 2022. The latest dividend was paid out to all shareholders who bought their shares by 11 August 2022 (the "ex-dividend date").

Have Novo Nordisk A/S's shares ever split?

Novo Nordisk A/S's shares were split on a 5:1 basis on 8 January 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk A/S shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Novo Nordisk A/S shares which in turn could have impacted Novo Nordisk A/S's share price.

Novo Nordisk A/S share price volatility

Over the last 12 months, Novo Nordisk A/S's shares have ranged in value from as little as $90.4 up to $121.5047. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk A/S's is 0.2894. This would suggest that Novo Nordisk A/S's shares are less volatile than average (for this exchange).

Novo Nordisk A/S overview

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease.

Frequently asked questions

What percentage of Novo Nordisk A/S is owned by insiders or institutions?
Currently 0.007% of Novo Nordisk A/S shares are held by insiders and 8.671% by institutions.
How many people work for Novo Nordisk A/S?
Latest data suggests 50,816 work at Novo Nordisk A/S.
When does the fiscal year end for Novo Nordisk A/S?
Novo Nordisk A/S's fiscal year ends in December.
Where is Novo Nordisk A/S based?
Novo Nordisk A/S's address is: Novo Allé 1, Bagsvaerd, Denmark, 2880
What is Novo Nordisk A/S's ISIN number?
Novo Nordisk A/S's international securities identification number is: US6701002056
What is Novo Nordisk A/S's CUSIP number?
Novo Nordisk A/S's Committee on Uniform Securities Identification Procedures number is: 670100205

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site